SynDevRx Gets $1.6M to develop drug to slow tumor growth
|June 5, 2013||Posted by Anharris under Cool Companies, Health, Innovation, Life Science|
My Cambridge Innovation Center lunch mates should be buying, today–having announced $1.6M in investments for their company SynDevRx, which develops drug candidates that target an enzyme that controls the vascular cells. As reported in today’s Boston Business Journal, Syn Dev Rx’s solution is based on a drug developed at Judah Folkman’s lab at Children’s Hospital Boston.
According to the BBJ: “Founded in 2007, SynDevRx is developing treatments for cancer and metabolic diseases including diabetes, obesity and fatty liver disease. ” The company says its technology increases a increases the activity of small molecule drugs by about 10 times, allowing for reduced doses, lower exposure and lower risk of toxicities. The company’s lead compound, SDX-7320, is in pre-clinical development for solid tumors.
In addition to executives Bradley Carver, CEO; James Shanahan, co-founder; and John Petersen, vice president of research and development, listed as directors on the filing are Eric Tooker, manager of Translational Accelerator LLC, a $20M biotech venture fund in Phoenix, Ariz. and Richard Love, managing partner at Translational and former CEO at both Triton Biosciences Inc. of Alameda, Calif. and ILEX Oncology Inc. of San Antonio, Texas.
–Anita M. Harris
Anita Harris is managing director of the Harris Communications Group, an award-winning public relations and digital marketing firm based in Cambridge, MA.